Aveanna Healthcare Holdings Inc

AVAH exhibits a strong parabolic up-move from its base breakout, supported by robust volume and relative strength. While the medium-term structure remains bullish within a Stage 2 advancing regime, price is extended and overbought in the short term. Execution is best deferred, stalking for a shallow pullback into the rising 9–20 EMA zone. A failure to hold this area would signal a loss of trend integrity.

• ↑Q2 revenue of $670M (+13.7% YoY) and adjusted EBITDA of $95.4M (+8%).
• ↑Preferred payer network at 37 agreements (64% of MCO volume), targeting 38 by 2026-end.
• ↓Persistent labor market pressure may constrain staffing and growth.